 |
|
|
| |
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR
MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
WEBCAST:
http://www.croiwebcasts.org/console/player/41308?mediaType=slideVideo&&crd_fl=0&ssmsrq=1554571949561&ctms=5000&csmsrq=5055
S Swindells,1 JF Andrade-Villanueva,2 GJ Richmond,3 G Rizzardini,4 A Baumgarten,5
M Masia,6 G Latiff,7 V Pokrovsky,8 JM Mrus,9 J Huang,10 KJ Hudson,9
DA Margolis,9 KY Smith,9 P Williams,11 WR Spreen9
1University of Nebraska Medical Center, Omaha, NE, United States; 2University of Guadalajara, Guadalajara, Mexico;
3Broward Health Medical Center, Fort Lauderdale, FL, United States; 4Fatebenefratelli Sacco Hospital, Milan, Italy;
5Center for Infectious Diseases, ZIBP, Berlin, Germany; 6Hospital General Universitario de Elche, Alicante, Spain; 7Maxwell Centre, Durban, South Africa; 8Central Research Institute of Epidemiology, Moscow, Russian Federation; 9ViiV Healthcare, Research Triangle Park, NC, United States;
10GlaxoSmithKline, Mississauga, ON, Canada; 11Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
